Barish H. Edil, MD,FACS
Surgical Oncologist
(75 Ratings)
, 51 Comments
VIEW ALL COMMENTS
About Barish Edil
Barish H. Edil, M.D., F.A.C.S., is Professor and Chair of the Department of Surgery at the University Of Oklahoma College Of Medicine. Before joining OU Health, he served as Professor of Surgery and chief of the Department of Surgery’s Division of Surgical Oncology at the University of Colorado at Denver School of Medicine.
A graduate of the University of Wisconsin, Dr. Edil holds a Bachelor in Science degree in Zoology. He received his Doctor of Medicine from the University of Wisconsin School of Medicine and then began his graduate medical education with his residency in General Surgery followed by his research fellowship in Surgical Oncology at the University of Oklahoma College of Medicine. After completing his residency training in General Surgery, he continued his career as the Assistant Chief of Service at the Johns Hopkins University School of Medicine receiving a certificate in surgical oncology. In addition, he completed his post-doctoral training in cancer immunology at The Johns Hopkins University.
After completion of his training, he remained at The Johns Hopkins School of Medicine as an Assistant Professor for the Department of Surgery and the Department of Oncology. While on the faculty, he performed the first laparoscopic Pancreaticoduodenectomy (“Whipple”) operation in the history of The Johns Hopkins Hospital. He also ran the first neo-adjuvant pancreatic cancer vaccine trial. He later joined the University of Colorado as the Division Chief of Surgical Oncology. While there, Dr. Edil was instrumental in pursuing a memorandum of understanding between the CU School of Medicine and the Zhejiang University College of Medicine, one of China’s premier medical institutions, for the transfer of knowledge and sharing of experiences and cutting-edge techniques for pancreas surgery residents and fellows thus promoting the globalization of stat-of-the-art healthcare. While at the University of Colorado, Dr. Edil’s team also discovered a new cancer vaccine, which is currently being developed for clinical trials.
Dr. Edil has authored over 140 peer-reviewed articles and book chapters in leading surgery textbooks. He has been an invited lecturer in the field of surgery, most notably in the areas of laparoscopic Whipple surgery, minimally invasive surgical oncology and cancer immunology. He is a fellow of the American College of Surgeons and is active in several national societies and review groups/study sections.
Affiliations
OU Health Stephenson Cancer Center,
OU Health Stephenson Cancer Center – Gastrointestinal Cancer Clinic
Awards
Named Oklahoma Top Doc in Surgical Oncology, 405 magazine
2022
405 Oklahoma Best Docs
2020
Outstanding Faculty, University of Oklahoma Health Sciences Center
2019
Castle Connolly Medical Ltd.
2016
5280 Colorado Top Docs
2016
Pioneer Award, University of Colorado
2016
Society of Surgical Oncology Poster of Distinction in Basic Science
2010
American Academy of Cancer Research, Clinical Trials Scholarship for Faculty
2008
Aesculapian Award Nominee
2006
Resident Research Forum Award University of Oklahoma Surgical Society
2003
Health Education
Medical School
Doctor of Medicine
University of Wisconsin School of Medicine Madison, WI 2000
Fellowship
Cancer Immunology
Johns Hopkins University School of Medicine Baltimore, MD 2008
Residency
General Surgery
University of Oklahoma Health Sciences Center Oklahoma City, OK 2006
Board Certification
American Board of Surgery
2007
American Academy of Cancer Research/American Society of Clinical Oncology
2008
Fellowship
David Mahoney Research Fellow, Surgical Oncology
Massachusetts General Hospital/Harvard Medical School Boston, MA 1997
H. Dale Collins Research Fellow, Surgical Oncology
University of Oklahoma Health Sciences Center Oklahoma City, OK 2002
Medical Interests
Areas of Interest:
Laparoscopic Whipple surgery Distal pancreatectomy Minimally invasive surgical oncology Minimally invasive pancreas surgery Gastric cancer cytoreductive surgery Intraperitoneal chemotherapy